Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
AGEN 
Agenus Inc (AGEN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: AGEN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $12.33
1 Year Target Price $12.33
| 1 | Strong Buy |
| 1 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -62.3% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 135.42M USD | Price to earnings Ratio - | 1Y Target Price 12.33 |
Price to earnings Ratio - | 1Y Target Price 12.33 | ||
Volume (30-day avg) 5 | Beta 1.62 | 52 Weeks Range 1.38 - 7.34 | Updated Date 08/28/2025 |
52 Weeks Range 1.38 - 7.34 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -7.06 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-11 | When - | Estimate -0.27 | Actual -1 |
Profitability
Profit Margin -162.69% | Operating Margin (TTM) -65.32% |
Management Effectiveness
Return on Assets (TTM) -23.93% | Return on Equity (TTM) -1278.83% |
Valuation
Trailing PE - | Forward PE 1.3 | Enterprise Value 216416459 | Price to Sales(TTM) 1.33 |
Enterprise Value 216416459 | Price to Sales(TTM) 1.33 | ||
Enterprise Value to Revenue 2.13 | Enterprise Value to EBITDA -2.42 | Shares Outstanding 31864100 | Shares Floating 31326879 |
Shares Outstanding 31864100 | Shares Floating 31326879 | ||
Percent Insiders 1.69 | Percent Institutions 30.09 |
Upturn AI SWOT
Agenus Inc
Company Overview
History and Background
Agenus Inc., formerly Antigenics Inc., was founded in 1994. It is a biopharmaceutical company focused on discovering and developing immunotherapies to treat cancers. The company evolved from vaccine development to checkpoint modulators and personalized cancer vaccines.
Core Business Areas
- Immuno-Oncology: Focuses on developing and commercializing therapies that activate the body's immune system to fight cancer. This includes checkpoint inhibitors, cell therapies, and adjuvants.
- Adjuvants: Agenus develops adjuvants designed to enhance the immune response to vaccines and immunotherapies.
Leadership and Structure
Dr. Garo H. Armen is the Chairman and CEO. The company has a typical organizational structure for a biotech firm, including research, development, clinical, and commercial departments. Jennifer Buell is the President and Chief Operating Officer.
Top Products and Market Share
Key Offerings
- BAL-0891: A tubulin-binding agent currently in clinical development for solid tumors. Specific market share data unavailable as it's still in development. Competitors in the tubulin inhibitor space include companies with drugs like paclitaxel and docetaxel.
- AGEN1181: An anti-CTLA-4 antibody in clinical development. Specific market share data unavailable as it's still in development. Competitors include Bristol Myers Squibb (Yervoy).
- QS-21 Stimulon Adjuvant: A key adjuvant component used in GSK's Shingrix vaccine. Specific revenue for Agenus from this is difficult to isolate, but royalties are a significant revenue driver. Competitors are other adjuvant developers.
Market Dynamics
Industry Overview
The immuno-oncology industry is experiencing significant growth, driven by advancements in understanding the immune system's role in fighting cancer. The market is competitive and rapidly evolving.
Positioning
Agenus is positioned as an innovative immunotherapy company focused on developing novel checkpoint inhibitors and adjuvants. Their competitive advantage lies in their discovery platform and diverse pipeline.
Total Addressable Market (TAM)
The total addressable market for cancer immunotherapy is estimated to be hundreds of billions of dollars. Agenus's positioning allows them to target specific segments within this market. Specific TAM data requires complex modelling and isn't available with the provided resources.
Upturn SWOT Analysis
Strengths
- Proprietary discovery platform
- Diverse pipeline of immuno-oncology assets
- Established partnership with GSK for QS-21 Stimulon adjuvant
- Experienced management team
Weaknesses
- High cash burn rate
- Reliance on partnerships for revenue generation
- Clinical trial risks and regulatory hurdles
- History of operating losses
Opportunities
- Potential for breakthrough therapies in underserved cancer markets
- Expansion of partnerships and collaborations
- Advancements in personalized cancer vaccines
- Acquisition by a larger pharmaceutical company
Threats
- Competition from larger pharmaceutical companies with established immuno-oncology portfolios
- Clinical trial failures
- Regulatory delays
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- BMY
- MRK
- PFE
- AZN
- GILD
Competitive Landscape
Agenus faces intense competition from larger pharmaceutical companies with deeper pockets and established market positions. Agenus's success hinges on its ability to develop and commercialize innovative therapies that address unmet needs in cancer treatment.
Major Acquisitions
Profectus BioSciences, Inc.
- Year: 2018
- Acquisition Price (USD millions): 40
- Strategic Rationale: Expanded Agenus's capabilities in personalized cancer vaccines and adoptive cell therapies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been dependent on partnership revenue and clinical trial progress. Agenus has experienced periods of volatility reflecting development milestones.
Future Projections: Future growth is dependent on the success of its clinical pipeline and commercialization efforts. Analyst estimates vary widely based on pipeline projections.
Recent Initiatives: Focus on advancing key clinical programs (BAL-0891, AGEN1181), expanding partnerships, and optimizing its discovery platform.
Summary
Agenus is a biotech company with promising immuno-oncology assets, but its financial health is a concern. Success depends on clinical trial outcomes and strategic partnerships. While the company has innovative approaches, competition is fierce and requires careful execution. Agenus should focus on advancing its clinical pipeline and securing additional funding. The need for cash burn has to be decreased.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports (where generally available and not behind a paywall)
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Agenus Inc
Exchange NASDAQ | Headquaters Lexington, MA, United States | ||
IPO Launch date 2000-02-04 | Founder, Executive Chairman & CEO Dr. Garo H. Armen Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 316 | Website https://www.agenusbio.com |
Full time employees 316 | Website https://www.agenusbio.com | ||
Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract t; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.